AstraZeneca announces tozorakimab met primary endpoint in Phase III trial

Positive high-level results from the Phase III Miranda trial showed potential first-in-class tozorakimab demonstrated a statistically significant and clinically meaningful reduction in the annualized rate of moderate-to-severe COPD exacerbations in the primary population of former smokers and in the overall population, which included former and current smokers, and patients across all blood eosinophil counts and all stages of lung function severity. In Miranda, patients received tozorakimab 300mg or placebo on top of standard of care once every two weeks. Tozorakimab was generally well tolerated with a favorable safety profile consistent with previous trials. The data will be submitted to regulatory authorities and shared with the scientific community at an upcoming medical meeting.